Major depressive disorder (MDD) is a highly prevalent disorder, which has been associated with an abnormal response of the hypothalamus-pituitary-adrenal (HPA) axis. Reports have argued that an abnormal HPA axis response can be due to an altered P-Glycoprotein (P-GP) function. This argument suggests that genetic polymorphisms in ABCB1 may have an effect on the HPA axis activity; however, it is still not clear if this influences the risk of MDD. Our study aims to evaluate the effect of ABCB1 C1236T, G2677TA and C3435T genetic polymorphisms on MDD risk in a subset of Portuguese patients. DNA samples from 80 MDD patients and 160 control subjects were genotyped using TaqMan Ò SNP Genotyping assays. A significant protection for MDD males carrying the T allele was observed (C1236T: odds ratio ( . No significant differences were observed regarding the overall subjects. Our results suggest that genetic variability of the ABCB1 is associated with MDD development in male Portuguese patients. To the best of our knowledge, this is the first report in Caucasian samples to analyze the effect of these ABCB1 genetic polymorphisms on MDD risk.
Introduction

M
ajor depressive disorder (MDD) is a highly prevalent disorder, with a lifetime risk of 10-25% in women and 5-12% in males (Compton et al., 2006) . Depression has been associated with an abnormal response of the hypothalamus-pituitary-adrenal (HPA) axis and some authors suggest that the normalization of HPA axis hyperactivity is a crucial step in remission (Holsboer, 2000; Binder et al., 2009) . Glucocorticoid hormones, secreted by the adrenal cortex, are potent modulators of neuronal activity and are involved in the maintenance of the basal activity of the HPA axis (Binder et al., 2009 ). The physiological access of endogenous glucocorticoids to the brain is important for HPA homeostasis. Studies in animal models have proved that the absence of PGlycoprotein (P-GP) function at the blood-brain barrier (BBB), leads to deep changes in the activity and regulation of the HPA system, suggesting that P-GP may regulate the HPA axis activity (Muller et al., 2003) . P-GP is an ATP-driven efflux pump involved in the pharmacokinetics of P-GP substrate drugs and in the efflux of toxic substances and metabolites, such as glucocorticoids (Kimchi-Sarfaty et al., 2007b) . This transporter molecule is encoded by the ABCB1 gene (also called MDR1), and is expressed on the epithelial cells of the intestine, canalicular membrane of hepatocytes, and on the endothelial cells of the BBB (Ambudkar et al., 1999) .
The overall ABCB1 activity depends on two parameters: the level of expression of the ABCB1 gene, which controls the amount of protein that is synthesized, and the functionality of the P-GP that determines transporter effectiveness and substrate recognition (Hoffmeyer et al., 2000) . Several singlenucleotide polymorphisms (SNPs) have been studied in the ABCB1 gene. Among these, polymorphisms in exon 12 (C1236T; rs1128503), in exon 21 (G2677TA; rs2032582), and exon 26 (C3435T; rs1045642) are the ones most reported (Hoffmeyer et al., 2000; Leschziner et al., 2007) . Studies regarding the effect of these ABCB1 polymorphisms on P-GP expression and function are not consensual (Borst and Elferink, 2002) . Regarding ABCB1 C1236T synonymous polymorphism, some reports found altered drug responses associated with 1236CC (Schaich et al., 2009 ) and 1236TT variants (Zhang et al., 2008) , while others were unable to find any relationship (Estrela Rde et al., 2009) . Reports regarding the influence of synonymous C3435T polymorphism are inconclusive (Hodges et al., 2011) , and the exact influence of this polymorphism is not known. Several lines of evidence have indicated that this polymorphism affects the expression (Hoffmeyer et al., 2000) and function (Compton et al., 2006) of P-GP, whereas others reported an altered P-GP conformation despite the fact that levels of mRNA and protein were similar (Kimchi-Sarfaty et al., 2007b) . Tri-allelic G2677TA nonsynonymous polymorphism has been also widely reported, since its variants are known to induce amino acid modification (Ala893 to Ser/ Thr893) (Leschziner et al., 2007) . This polymorphism is also known to affect P-GP functionality (Hodges et al., 2011) .
Despite functional studies, investigations focusing on the influence of P-GP polymorphisms and the risk of depression are scarce and have only been conducted in Asian (Qian et al., 2006; Fujii et al., 2012) and Mexican American patients (Dong et al., 2009) . This article examines whether common genetic polymorphisms in the ABCB1 gene, previously reported to be associated with antidepressant responses, might be a predictor of risk for MDD in a subset of Portuguese patients.
Materials and Methods
Patients
From a total of 92 Portuguese MDD patients followed in a 18-month follow-up study at Magalhã es Lemos Hospital, 80 patients agreed to participate in the genetic study (21 males and 59 females), aged 18-60, with a median age of 41.5 years (mean age 40.48; standard deviation 11.06). Participants in the clinical sample were recruited in the outpatient clinic at the Magalhã es Lemos Hospital and as part of a broader research on the social-cognitive predictors of pharmacological responses to depression (Carvalho, 2012) . Patients with the suspicion of depression were sent to the clinic by their family doctor and those whose clinical interview confirmed the diagnosis of depression were submitted to further evaluation for major depression using the Structured Clinical Interview for DSM Axis I Disorders (SCID-I), and for personality disorders using the Axis II Disorders (SCID-II). Subjects with more than one previous depressive episode, chronic depression, severe physical illness, psychiatric disorders with psychotic symptoms, substance dependence, or personality disorders were excluded from the study. Age-and gendermatched healthy control individuals were recruited from the same city. These healthy controls consisted of 160 individuals (42 males and 118 females) with median age of 41 years (mean age 40.48; standard deviation 11.08), collected among the blood donors of the Portuguese Institute of Oncology-Porto. The blood donors completed a health questionnaire, and were interviewed by a physician about their medications and possible chronic illnesses. The study was approved by the ethics committee of Magalhã es Lemos Hospital. Written informed consent according to The Code of Ethics of the World Medical Association (Declaration of Helsinki) was obtained from each individual after explanation of the study.
Sample collection and DNA extraction
Peripheral blood samples were collected following the standard venipuncture technique in EDTA-containing tubes, and the genomic DNA was extracted from the whole blood with a commercial kit (E.Z.N.A.-Omega Bio-tek, Norcross, USA), according to the manufacturer's instructions and stored at -20°C.
C1236T, G2677TA, C3435T ABCB1 polymorphism analysis
The C1236T, G2677TA, C3435T ABCB1 polymorphism analysis was carried using TaqMan Ò SNP Genotyping Assays C___7586662_10; C_11711720C_30 and C_11711720D_40; C___7586657_20, respectively (Applied Biosystems, Foster City, CA). Reactions were performed on an Applied Biosystems 7300 Real Time PCR System (Applied Biosystems) with a 5 mL final volume mixture containing 1 · TaqMan Genotyping Master Mix (Applied Biosystems), 900 nM of each primer, 200 nM of probes labeled with either FAM or VIC, and 10 ng of extracted DNA. Thermal cycling conditions were 10 min at 95°C followed by 45 cycles (or 50 cycles for G2677TA) of 15 s at 95°C and 1 min at 60°C. Allelic discrimination was performed by measuring endpoint fluorescence using an ABI PRISM Ò 7300 Sequence Detection System (Applied Biosystems). Genotyping data were read blind to the clinical course of illness and, in case of ambiguous genotypic data, experiments were repeated for determining the genotype of every individual.
Statistical analysis
Data preparation and analysis were carried out using the computer software PAWS Statistics 18 (release 18.0.0) and Epi Info (version 6.04a). A 5% level of significance was used in the chi-square (v 2 ) analysis to compare the categorical variables. The odds ratio (OR) and 95% confidence interval (CI) were calculated as a measure of association between genotypes and MDD risk. The Fisher's exact test was used for tables containing cells, where values are less than five individuals. The Hardy-Weinberg equilibrium was tested by a v 2 test to compare the observed versus the expected genotype frequencies. Measures of linkage disequilibrium (LD), represented as D¢ and r discovery rate (FDR) method. A posteriori power analysis was performed using Quanto software (version 1.0; http:// hydra.usc.edu/gxe) with input of the following variables: case-control study design, significance level (a) < 0.05 (two sided), model of inheritance = log additive, minor allele frequency = 0.406, and genetic effect for OR ( ‡ 1.75 and £ 0.55). This study achieved a statistical power of 80% for the minor allele of ABCB1 C1236T, which exhibited the lowest allele frequency among the three polymorphisms.
Results
Allele and genotype frequencies of ABCB1 gene
The genotype and allele frequencies of the ABCB1 C1236T, C3435T and C2677TA polymorphisms are shown in Table 1 . No significant deviations from the Hardy-Weinberg equilibrium proportions were observed both in controls and cases (Table 1) . LD pairwise analysis revealed a strong LD between C1236T and G2677TA (D¢ = 0.88, r 2 = 0.75) and C3435T and G2677TA (D¢ 0.83, p = 0.59), while C1236T and C3435T loci were in moderate LD (D¢ = 0.67, r 2 = 0.40).
Allele and genotype association with MDD risk
To estimate the influence of ABCB1 polymorphisms in the development of MDD, allele and genotype frequencies were compared between MDD patients and controls. Our results did not reveal any statistically significant association (Table 1) Nevertheless, when data were stratified according to gender, a significant association was verified among male patients (Table 2) 
Haplotype association with MDD risk
To estimate the combined influence of ABCB1 polymorphisms in the risk of MDD development, haplotype analysis was carried out. A total of seven different haplotypes were identified using the SVS software (Table 3) . Although haplotype analysis did not reveal any significant association with MDD diagnosis regarding the overall subjects, TTT haplotype was associated to a lower risk of MDD development in male subjects (OR = 0.313, 95% CI: [0.118-0.832], p = 0.016). The association remained statistically significant after multiple comparisons adjustment (FDR p = 0.032).
Comparison of ABCB1 genotype frequencies with reports from the literature
To verify if our control subjects are similar to other Caucasian populations, we compared the frequencies of the genetic polymorphisms evaluated in this study with the observed frequencies in the control samples from other reports. Genotype and allele frequencies of our controls were not different from what is reported in the literature, regarding the Portuguese population (C1236T: v 2 = 4.81, DF = 2, p = 0.09; G2677TA: v 2 = 4.84, DF = 2, p = 0.089; C3435T: v 2 = 4.79; DF = 2; p = 0.091). 14 SANTOS ET AL.
Genotype frequency distribution of the C1236T SNP in our study group was not significantly different than other Caucasian populations, such as Czech, French, German, and Hungarian. However, significant differences were found with other ethnic groups, such as Chinese, Indian, Japanese, Turkish, and Malay populations (Table 4) . Similar results were found for G2677TA (Table 4) . Concerning C3435T polymorphism, no significant differences were found between our study and the Mediterranean populations. However, significant differences were found for other Caucasian populations such as British, German, Hungarian, Czech, and Polish (Table 4) .
Discussion
We investigated three common SNPs in the ABCB1 gene (C1236T, G2677TA and C3435T) in a subset of Portuguese patients with MDD. To the best of our knowledge, no reports have been published in Caucasian populations regarding the effect of these ABCB1 genetic polymorphisms on MDD risk. Furthermore, the previous reports associating the risk of MDD and functional polymorphisms in ABCB1 were conducted in Asian populations, and have only evaluated the effect of C1236T and C3435T polymorphisms in haplotype analysis. We included in the study, a third polymorphism in the ABCB1 haplotype analysis, the triallelic G2677TA functional genetic polymorphism. We demonstrated a significant protection for MDD only in males carrying the T allele in the evaluated polymorphisms. Moreover, the haplotype analysis revealed that male individuals carrying the TTT haplotype have nearly 70% less risk of developing MDD. Overall, the case-control analysis showed no association between the risk of MDD and the presence of a specific allele, genotype, or haplotype. Our results seem to indicate that the influence of ABCB1 functional polymorphism in the risk of MDD is gender specific.
Although several reports addressed the influence of these ABCB1 genetic polymorphisms in antidepressant responses, only two studies have evaluated the association of these common polymorphisms in the ABCB1 gene and the risk of depression (Qian et al., 2006; Fujii et al., 2012) . Fujii et al. (2012) observed, in a large group of Japanese subjects that, carriers of the 3435T allele or 1236T-3435T haplotype were more common in patients than in controls, suggesting that C3435T may (Sapmaz et al., 2008) Bold values indicate p < 0.05.
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have a role in MDD development risk. However, regarding the triallelic SNP, G2677TA, the authors did not find any significant differences in allelic and genotypic frequencies between cases and controls. In another study, Qian et al. (2006) evaluated the effect of C3435T and G2677TA polymorphisms in mood disorders, including depression. No significant association between this C3435T polymorphism and the risk of developing mood disorder was found, but a higher frequency of 2677A was observed in patients with mood disorders than in controls ( p < 0.05) (Qian et al., 2006) . The putative reasons for these discrepancies are widely discussed in the article by Fujii et al. (2012) , and are related to the sample size and the heterogeneity of the patients used in the Qian et al. (2006) study. We observed that the TT genotype in C3435T was less common in male cases than in controls and this points to a different direction when compared to the reports of Fujii et al. (2012) and Qian et al. (2006) . These nonconcordant results may be explained by two lines of evidence. First, both studies evaluated MDD risk in Asian subjects. The genetic variability of the ABCB1 polymorphisms is known to diverge among ethnic groups (Ameyaw et al., 2001; Sipeky et al., 2011) , as shown in Table 4 . Second, no stratification on gender was present in these studies. As proposed by Becker et al., (2009) gender stratification is essential when evaluating the effect of these ABCB1 polymorphisms, since they are found to be associated with the cholesterol-lowering effect of simvastatin only in males. Additionally, it has been proposed by several authors that different susceptibility of depression is under the major influence of gender (Unschuld et al., 2010) .
Haplotype analysis in ABCB1 polymorphisms, rather than a single SNP, may provide an advantage in the diagnosis of complex diseases, such as MDD. In fact, there are reports of significant correlations found using ABCB1 1236T-2677T-3435T haplotype analysis and lack of association when each SNP was analyzed separately (Potocnik et al., 2004; KimchiSarfaty et al., 2007a) . We observed that the ABCB1 1236T-2677T-3435T haplotype presents a protective effect since the male carriers of this profile have a lower risk of developing MDD (OR = 0.313, , p = 0.016). Clinical studies have shown that the 1236T-2677T-3435T haplotype is also associated with reduced P-GP activity (Salama et al., 2006) . Indeed, recombinant cells expressing ABCB1 1236T-2677T-3435T variants displayed only 0-22.7% transporter activity, which suggests that this haplotype significantly reduces P-GP functionality in vitro, losing about 80%-100% of its efflux capability (Salama et al., 2006) . Although some authors defend that the lack of P-GP function could lead to the accumulation of deleterious substances, such as neurotoxins, and represent a risk of MDD development (Fujii et al., 2012) , we hypothesized that male carriers of the 1236T-2677T-3435T haplotype may have a less active transporter and this might be protective for the risk of MDD. P-GP is known to in vivo regulate brain access of endogenous steroid hormones (Uhr et al., 2002; Binder et al., 2009) . In normal subjects, the HPA axis is regulated by a negative feedback control, whereby glucocorticoids secreted from the adrenal gland suppress the hypothalamus to secret the corticotrophin releasing hormone (CRH) and arginine-vasopressin, which per se limits the release of corticotrophin (ACTH) from the anterior pituitary, and thus promotes less glucocorticoid release from adrenal glands (O'Brien et al., 2012) . In depressed patients, this negative feedback control is impaired and patients display HPA axis hyperactivity, evident by an increased cortisol concentration in serum, urine, and the cerebrospinal fluid (Holsboer, 2000; Pariante and Miller, 2001) .
Our hypothesis is that the putative lower P-GP function, found in carriers of the 1236T/2677T/3435T haplotype, may restrain HPA system activation after stressful events, and induce a chronically increased negative feedback at the hypothalamic level due to an enhanced penetration of glucocorticoid hormones into the central nervous system, and promote a less active HPA response under stress conditions. Interestingly, in vivo studies using abcb1ab ( -/ -) mice mutants prove that the absence of P-GP leads to an increased penetration of corticosteroid hormones in the central nervous system, which in turn, enhanced central negative feedback inhibition of stress hormone secretion, with lower plasma ACTH levels in both at basal and under stress conditions (Muller et al., 2003) . Moreover, antidepressants have also inhibited P-GP in vitro, and decreased the HPA axis activity in vivo, leading to the hypothesis that antidepressants inhibit P-GP at the BBB and increase glucocorticoid access to the brain (Yau et al., 2007) .
The gender-specific trait of our results can be explained by the differential expression of P-GP in male and female (Suzuki et al., 2006; Bebawy and Chetty, 2009) . Sex hormones can regulate the expression of P-GP in systemic organs, contributing to the differences observed in metabolic disposition (Compton et al., 2006) . Interestingly, the male androgens suppress P-GP expression and function, contrary to what is reported for the female sex hormones, but the precise mechanism for testosterone repression of P-GP expression remains undefined (Suzuki et al., 2006) . Moreover, a distinct HPA axis activation among male and female might explain our results. Binder et al., (2009) observed a normalization of HPA axis reactivity, illustrated by the dexamethasone-resistant test, only among male patients with remission of depressive symptoms. Another report showed that knockdown of glucocorticoid receptors in the medial prefrontal cortex, hippocampus, and basolateral amygdala induces depression-like behaviors in male mice, but not in females (Solomon et al., 2012) . This author suggests that this mechanism for development of mood disorders holds only in males and provable symptoms of depression are mediated by an alternative brain circuitry and/or different molecular substrates in comparison with female gender individuals (Solomon et al., 2012) . Additionally, several reports in the literature regarding depression and antidepressant responses, point out for differences among male and female patients (Schaich et al., 2009; Kurita et al., 2012) . The absence of a significant association in women found in our study does not exclude the fact that genetic variation in ABCB1 does affect the risk of MDD development in women, but the effect is most likely weaker in women than in males.
The main limitation of our study is the relatively low number of subjects genotyped. Major concerns of small sample studies are false-positive results and over-estimation of magnitude association. To exclude false-positive results, FDR correction was included for multiple comparisons, and our results remain statistically significant for the TTT haplotype. In this study, high magnitude associations (OR ‡ 1.75 and £ 0.55) are detected with an 80% statistical power, like the one we found for the male TTT haplotype. However, it is possible that small effects are not detected with our sample. Control selection bias was excluded by comparing genotypic frequencies of our controls and other southern Caucasian samples, including Portuguese. Although our study was the first to analyze the influence of ABCB1 C1236T, C3435T and G2677TA polymorphisms in a Caucasian subset of MDD patients, independent association studies with larger sample sizes are needed to confirm the influence of these SNPs in MDD development risk.
In conclusion, this article adds clinical evidence that genetic variability of the ABCB1 is associated with MDD in males, and that this may influence the HPA system activity, through a less active P-GP. The observed sex differences in ABCB1 polymorphisms and risk of MDD may explain a gender dimorphic sensitivity of the HPA axis and hypothetically reflect a gender-specific pathophysiology of depression.
